[go: up one dir, main page]

DE60021700D1 - Formulierungen enthaltend antisense nukleotide spezifisch für connexine - Google Patents

Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Info

Publication number
DE60021700D1
DE60021700D1 DE60021700T DE60021700T DE60021700D1 DE 60021700 D1 DE60021700 D1 DE 60021700D1 DE 60021700 T DE60021700 T DE 60021700T DE 60021700 T DE60021700 T DE 60021700T DE 60021700 D1 DE60021700 D1 DE 60021700D1
Authority
DE
Germany
Prior art keywords
connexine
formulations containing
antisense nucleotide
containing antisense
nucleotide specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021700T
Other languages
English (en)
Other versions
DE60021700T2 (de
Inventor
David Laurence Becker
Colin Richard Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60021700D1 publication Critical patent/DE60021700D1/de
Publication of DE60021700T2 publication Critical patent/DE60021700T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
DE60021700T 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine Expired - Lifetime DE60021700T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ33392899 1999-01-27
NZ33392899 1999-01-27
NZ50019099 1999-10-07
NZ50019099 1999-10-07
PCT/GB2000/000238 WO2000044409A1 (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides to connexins

Publications (2)

Publication Number Publication Date
DE60021700D1 true DE60021700D1 (de) 2005-09-08
DE60021700T2 DE60021700T2 (de) 2006-06-01

Family

ID=26652011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021700T Expired - Lifetime DE60021700T2 (de) 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Country Status (13)

Country Link
US (11) US7098190B1 (de)
EP (3) EP1621212B1 (de)
JP (4) JP4994533B2 (de)
AT (2) ATE533515T1 (de)
AU (1) AU776512B2 (de)
CA (2) CA2361251C (de)
CY (2) CY1112557T1 (de)
DE (1) DE60021700T2 (de)
DK (3) DK1621212T3 (de)
ES (3) ES2245638T3 (de)
NZ (1) NZ513154A (de)
PT (3) PT2314321E (de)
WO (1) WO2000044409A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5991308A (ja) * 1982-11-16 1984-05-26 Kawasaki Heavy Ind Ltd 平面の検出方法
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine
EP1197553A1 (de) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense-Nukleinsäure gegen das alphaV Integrin
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US8034789B2 (en) 2003-12-03 2011-10-11 Coda Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
EP1827480B1 (de) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Zusammensetzungen und methoden zur wundheilung und geweberegenerierung
AU2006257283A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
JPWO2007055224A1 (ja) * 2005-11-08 2009-04-30 関西ティー・エル・オー株式会社 角膜疾患治療剤
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
RU2542471C2 (ru) * 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
CA2672220A1 (en) * 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
AU2014204482B2 (en) * 2006-12-11 2016-07-07 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
JP5552048B2 (ja) * 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
US8614309B2 (en) 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
CA2709151A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009085275A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
WO2009085272A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
JP2011507857A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用
CA2710388A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
CA2710232A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
US20110245184A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of surgical adhesions
CA2710227A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
WO2009085271A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
CN102239260B (zh) 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
CA2746003C (en) 2008-12-04 2020-03-31 Opko Curna, Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
KR101840618B1 (ko) 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
ES2629630T3 (es) 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
US8669941B2 (en) * 2009-01-05 2014-03-11 Nuance Communications, Inc. Method and apparatus for text entry
ES2560107T3 (es) 2009-02-12 2016-02-17 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102482677B (zh) 2009-03-16 2017-10-17 库尔纳公司 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
CA2755404C (en) 2009-03-17 2020-03-24 Joseph Collard Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP2427553A4 (de) 2009-05-06 2012-11-07 Opko Curna Llc Behandlung von lipidtransport- und stoffwechselgenbedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein lipidtransport- und stoffwechselgen
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
JP6128846B2 (ja) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
ES2583691T3 (es) 2009-06-26 2016-09-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
JP2013500017A (ja) 2009-07-24 2013-01-07 カッパーアールエヌエー，インコーポレイテッド サ−チュイン（ｓｉｒｔ）への天然アンチセンス転写物の阻止によるサ−チュイン（ｓｉｒｔ）関連疾患の治療
EP2462229B1 (de) 2009-08-05 2016-05-11 CuRNA, Inc. Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
CN102625841A (zh) 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
CA2771228C (en) 2009-08-21 2020-12-29 Opko Curna, Llc Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR101892760B1 (ko) 2009-08-25 2018-08-28 큐알엔에이, 인크. ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
JP6175236B2 (ja) 2009-09-25 2017-08-09 カッパーアールエヌエー，インコーポレイテッド フィラグリン（ｆｌｇ）の発現および活性の調整によるｆｌｇ関連疾患の処置
NO2513310T3 (de) 2009-12-16 2018-03-31
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
NO2516648T3 (de) 2009-12-23 2018-04-07
KR101838305B1 (ko) 2009-12-29 2018-03-13 큐알엔에이, 인크. ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
KR101853508B1 (ko) 2009-12-29 2018-06-20 큐알엔에이, 인크. 종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
CN102791862B (zh) 2009-12-31 2017-04-05 库尔纳公司 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
CN102906264B (zh) 2010-01-04 2017-08-04 库尔纳公司 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
JP5963680B2 (ja) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
JP5981850B2 (ja) 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
RU2612884C2 (ru) 2010-04-02 2017-03-13 Курна, Инк. Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
KR101936011B1 (ko) 2010-05-03 2019-01-07 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8980858B2 (en) 2010-05-26 2015-03-17 Curna, Inc. Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
KR101914309B1 (ko) 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
ES2657590T3 (es) 2010-11-23 2018-03-06 Curna, Inc. Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
TWI678375B (zh) 2011-06-09 2019-12-01 可娜公司 藉由抑制共濟蛋白（ｆｒａｔａｘｉｎ，ｆｘｎ）之天然反股轉錄本治療ｆｘｎ相關疾病
CN103874486A (zh) 2011-09-06 2014-06-18 库尔纳公司 用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
WO2013122778A1 (en) 2012-02-15 2013-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
JP6185937B2 (ja) 2012-03-01 2017-08-23 ファーストストリング・リサーチ・インコーポレイテッドＦｉｒｓｔｓｔｒｉｎｇ Ｒｅｓｅａｒｃｈ，Ｉｎｃ． アルファコネキシンｃ末端（ａｃｔ）ペプチド含有局所用ゲル剤
EP2825648B1 (de) 2012-03-15 2018-09-05 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
JP2015513905A (ja) 2012-03-27 2015-05-18 コーダ セラピューティクス， インコーポレイテッド カドヘリン調節に基づく組成物および処置
WO2014164805A1 (en) * 2013-03-11 2014-10-09 University Of North Carolina At Chapel Hill Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP3077050B1 (de) * 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Verfahren zur behandlung von wundheilung mit chemisch modifizierten oligonukleotiden
CA2940648A1 (en) * 2014-02-25 2015-09-03 Coda Therapeutics, Inc. Treatment of resistant lesions
US20170106047A1 (en) * 2014-06-12 2017-04-20 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CA3015839A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
EP3685824A1 (de) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Zusammensetzung zur verabreichung und freisetzung von oligonukleotiden
CN116710474A (zh) 2020-10-22 2023-09-05 撒凯尔生物公司 肽制剂及其眼科用途
US20250289864A1 (en) * 2022-05-13 2025-09-18 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
JP2000504670A (ja) * 1996-01-31 2000-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍細胞の成長を抑制する方法
DE69736820T2 (de) * 1996-03-07 2007-08-09 Eisai Co., Ltd. Mäuse Adhesions Molekül Occludin
AU2458597A (en) * 1996-07-17 1998-02-09 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
EP0950060A4 (de) * 1996-12-02 2000-07-05 Dyad Pharmaceutical Corp Gegenstrang-hemmung von menschlichen adhäsionsmolekülen
WO1999029858A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression

Also Published As

Publication number Publication date
US7919474B2 (en) 2011-04-05
EP1621212B1 (de) 2011-11-16
AU776512B2 (en) 2004-09-09
EP2314321A1 (de) 2011-04-27
US9193754B2 (en) 2015-11-24
JP5736397B2 (ja) 2015-06-17
EP1146908B1 (de) 2005-08-03
US7879811B2 (en) 2011-02-01
US20080221051A1 (en) 2008-09-11
CY1115521T1 (el) 2017-01-04
US20070037765A1 (en) 2007-02-15
ATE300959T1 (de) 2005-08-15
ATE533515T1 (de) 2011-12-15
DK2314321T3 (da) 2014-09-08
ES2245638T3 (es) 2006-01-16
EP2314321B1 (de) 2014-06-04
US8314074B2 (en) 2012-11-20
CA2730386A1 (en) 2000-08-03
NZ513154A (en) 2004-01-30
CY1112557T1 (el) 2016-02-10
US7098190B1 (en) 2006-08-29
JP5705890B2 (ja) 2015-04-22
EP1621212A1 (de) 2006-02-01
DE60021700T2 (de) 2006-06-01
US20110065770A1 (en) 2011-03-17
JP2013135677A (ja) 2013-07-11
JP2002535377A (ja) 2002-10-22
US20070078103A1 (en) 2007-04-05
PT1146908E (pt) 2005-10-31
US20070072820A1 (en) 2007-03-29
US7615540B2 (en) 2009-11-10
DK1621212T3 (da) 2012-03-05
JP2013136594A (ja) 2013-07-11
CA2361251A1 (en) 2000-08-03
PT2314321E (pt) 2014-09-26
US20070060538A1 (en) 2007-03-15
US20080249041A1 (en) 2008-10-09
WO2000044409A1 (en) 2000-08-03
DK1146908T3 (da) 2005-10-10
EP1146908A1 (de) 2001-10-24
US7902164B2 (en) 2011-03-08
CA2361251C (en) 2011-03-08
US20070072819A1 (en) 2007-03-29
CA2730386C (en) 2015-08-11
JP4994533B2 (ja) 2012-08-08
ES2498745T3 (es) 2014-09-25
AU2119300A (en) 2000-08-18
ES2377749T3 (es) 2012-03-30
PT1621212E (pt) 2012-02-20
US20070066555A1 (en) 2007-03-22
JP2012041342A (ja) 2012-03-01
US20130079388A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
DE60021700D1 (de) Formulierungen enthaltend antisense nukleotide spezifisch für connexine
EP1041880A4 (de) Verabreichung von arginin zur erzielung eines wohltuenden effektes
DE59911740D1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
BR0204596A (pt) Composição tópica, e, métodos para melhorar a aparência estética da pele, para intensificar a eficácia terapêutica de uma composição tópica para a pele, unha, lábios e/ou cabelo e para intensificar a produção de um constituinte de célula de planta predeterminada
DE69634430D1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
AU2001240940A1 (en) Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care
WO2000078341A8 (en) A method for the prophylaxis and/or treatment of medical disorders
PT1009425E (pt) Cicatrizacao de feridas
EP0471135B1 (de) Haarwuchsmittel
FR2865651B1 (fr) Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
BR0116293A (pt) Composição tópica, e, método para prevenir, melhorar ou tratar a hiperpigmentação da pele
IT1258069B (it) Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli
RU93002420A (ru) Способ лечения раны
MXPA04012527A (es) Tratamientos para el cabello y las unas usando alcanolaminas.
GB9715085D0 (en) Gene therapy vehicle
WO1996001100A3 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
US20180085295A1 (en) Hair Growth Composition
WO2000002601A3 (en) Transdermal delivery system
PT1140001E (pt) Composicao para tratamento de queimaduras
WO2002098515A3 (en) Topical treatments using alkanolamines
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
ES2212753B2 (es) Formula que frena la alopecia y favorece el nacimiento del cabello.
KR20230036638A (ko) 탈모방지 및 발모촉진용 마이크로니들 패치 및 그 제조방법
Maghinay et al. Can Minoxidil on Beard Helps with Patchy Beards Growth?

Legal Events

Date Code Title Description
8364 No opposition during term of opposition